SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Discussion is centered on Capricors 24-month HOPE-3 open-label extension data for deramiocel, with traders highlighting slower upper-limb decline after placebo patients switched to treatment as supportive evidence for the Duchenne muscular dystrophy therapy. Bulls see the results as strengthening the pending FDA application, while skeptics question how the open-label findings and disputed statistical analysis plans will affect the agencys decision.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA administrative judges pause of the broader cannabis rescheduling case, while considering whether to add a GAO report on agency procedures to the record, has delayed a closely watched Schedule III catalyst for MSOS and weighed on sentiment. Traders are split between viewing the pause as a limited procedural delay and buying opportunity, and fearing rescheduling will take much longer or lose momentum.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is under pressure amid concerns that Kalshi and Polymarket are diverting wagering activity from traditional sportsbooks, with legal uncertainty around prediction markets adding to broader betting-sector weakness. Bears worry that competition and investment will squeeze margins, while bulls point to DKeXs growth and argue that tighter rules on rivals could benefit DraftKings.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming fiscal Q4 results and guidance dominate discussion, with traders focused on whether tight memory supply and AI-driven demand can sustain pricing and growth. Many expect strong results, while others warn that optimism may already be priced in and debate the memory cycles durability and risk of a sell-the-news reaction.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

The FHFAs move to include VantageScore alongside FICO in mortgage pricing has triggered a sharp selloff, as traders worry that new competition could erode FICOs market share and pricing power. The community is split between expecting further pressure on the mortgage-scoring business and viewing the decline as an overreaction, noting that adoption is not yet fully implemented and FICO remains established in lending.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, attributed to stronger demand for its cancer treatments, is driving the sharp rally, with analyst upgrades adding to the optimism. Traders are debating whether the move reflects improving commercial momentum or a short squeeze, while some warn of profit-taking and possible dilution ahead of upcoming lung-cancer data.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase 3 results for Vandas HETLIOZ in delayed sleep-wake phase disorder are driving attention, with traders highlighting that the study met its primary endpoint. The community is largely celebrating the clinical milestone, though some question whether the news will translate into lasting share-price gains.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A judges pause in the broader cannabis rescheduling case has delayed the administrative judges recommendation, unsettling TRLV and other cannabis stocks. Traders debate whether the resulting selloff reflects a meaningful setback or a temporary delay, with some arguing Trulieve remains supported by its medical-cannabis business and existing Schedule III treatment for qualifying medical products.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energys fiscal 2026 results have put production growth and its ramp-up at Burke Hollow in focus, alongside a debt-free balance sheet and substantial liquidity. Traders are split over the report: bulls see operating progress and a stronger uranium-production story, while skeptics point to continued losses and question the sell-off despite higher output.

Lighter is a decentralized trading platform built for unmatched security and scale. It’s the first exchange to offer verifiable order matching and liquidations while delivering best-in-class performance on par with traditional exchanges.

lighter

LIT is drawing attention after a sharp pullback from its recent run, with traders debating whether it reflects profit-taking, concern about upcoming token unlocks, or an unconfirmed negative catalyst. Some are calling the move a rug, while others are buying the dip and maintaining a bullish view.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BrightSpring vs. Option Care Health: Which Healthcare Stock Is Better?

BrightSpring's faster growth, pharmacy and provider-service expansion, and improving margins contrast with OPCH's slower growth and chronic-therapy pressures.

Are Investors Undervaluing Aveanna Healthcare (AVAH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?

BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.

Should Value Investors Buy Option Care Health (OPCH) Stock?

Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?

BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.

Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare

Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.

4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds

An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.

OPCH or CHE: Which Is the Better Value Stock Right Now?

OPCH vs. CHE: Which Stock Is the Better Value Option?

Are Investors Undervaluing Option Care Health (OPCH) Right Now?

Option Care Health, Inc. engages in the provision of home and alternate site infusion services. The firm provides infusion therapy and other ancillary healthcare services through a national network of full-service pharmacies. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Its home infusion services consist of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions. The company was founded in 1996 and is headquartered in Bannockburn, IL.

Option Care Health Inc. - Registered Shares

Bearish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$22.81
Prev Close	$22.90
Open	$22.71
Dividend Yield	0.00%
50-Day Moving Average	$23.45
Beta	0.43
Avg. Volume	2.04M
PE Ratio	17.26

52-Week High	$36.80
52-Week Low	$18.01
Market Capitalization	$3.43B
EPS (Annual)	$1.27
Price to Book	2.71
Revenue Per Employee	$865,428.77

Feed

News

Sentiment

Earnings

Fundamentals

Info

OPCH Fundamentals